197 related articles for article (PubMed ID: 35561303)
1. More to the RAS Story: KRAS
Lietman CD; Johnson ML; McCormick F; Lindsay CR
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35561303
[TBL] [Abstract][Full Text] [Related]
2. Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRAS
Ryan MB; Fece de la Cruz F; Phat S; Myers DT; Wong E; Shahzade HA; Hong CB; Corcoran RB
Clin Cancer Res; 2020 Apr; 26(7):1633-1643. PubMed ID: 31776128
[TBL] [Abstract][Full Text] [Related]
3. KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
Nagasaka M; Li Y; Sukari A; Ou SI; Al-Hallak MN; Azmi AS
Cancer Treat Rev; 2020 Mar; 84():101974. PubMed ID: 32014824
[TBL] [Abstract][Full Text] [Related]
4. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
Holderfield M; Lee BJ; Jiang J; Tomlinson A; Seamon KJ; Mira A; Patrucco E; Goodhart G; Dilly J; Gindin Y; Dinglasan N; Wang Y; Lai LP; Cai S; Jiang L; Nasholm N; Shifrin N; Blaj C; Shah H; Evans JW; Montazer N; Lai O; Shi J; Ahler E; Quintana E; Chang S; Salvador A; Marquez A; Cregg J; Liu Y; Milin A; Chen A; Ziv TB; Parsons D; Knox JE; Klomp JE; Roth J; Rees M; Ronan M; Cuevas-Navarro A; Hu F; Lito P; Santamaria D; Aguirre AJ; Waters AM; Der CJ; Ambrogio C; Wang Z; Gill AL; Koltun ES; Smith JAM; Wildes D; Singh M
Nature; 2024 May; 629(8013):919-926. PubMed ID: 38589574
[TBL] [Abstract][Full Text] [Related]
5. Targeting PI3Kα overcomes resistance to KRas
Qi WL; Li HY; Wang Y; Xu L; Deng JT; Zhang X; Wang YX; Meng LH
Acta Pharmacol Sin; 2023 May; 44(5):1083-1094. PubMed ID: 36411339
[TBL] [Abstract][Full Text] [Related]
6. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism.
Lito P; Solomon M; Li LS; Hansen R; Rosen N
Science; 2016 Feb; 351(6273):604-8. PubMed ID: 26841430
[TBL] [Abstract][Full Text] [Related]
7. Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy.
Kirschner T; Müller MP; Rauh D
J Med Chem; 2024 Apr; 67(8):6044-6051. PubMed ID: 38621359
[TBL] [Abstract][Full Text] [Related]
8. Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy.
Boumelha J; Molina-Arcas M; Downward J
Clin Cancer Res; 2023 Dec; 29(24):5012-5020. PubMed ID: 37581538
[TBL] [Abstract][Full Text] [Related]
9. Targeting KRAS Oncogene for Patients With Colorectal Cancer: A New Step Toward Precision Medicine.
Sahin IH; Saridogan T; Ayasun R; Syed MP; Gorantla V; Malhotra M; Thomas R; Rhee J; Zhang J; Hsu D; Singhi AD; Saeed A
JCO Oncol Pract; 2024 May; ():OP2300787. PubMed ID: 38739872
[No Abstract] [Full Text] [Related]
10. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition.
Xue JY; Zhao Y; Aronowitz J; Mai TT; Vides A; Qeriqi B; Kim D; Li C; de Stanchina E; Mazutis L; Risso D; Lito P
Nature; 2020 Jan; 577(7790):421-425. PubMed ID: 31915379
[TBL] [Abstract][Full Text] [Related]
11. Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients.
Kim D; Xue JY; Lito P
Cell; 2020 Nov; 183(4):850-859. PubMed ID: 33065029
[TBL] [Abstract][Full Text] [Related]
12. KRAS G12C inhibitor combination therapies: current evidence and challenge.
Miyashita H; Kato S; Hong DS
Front Oncol; 2024; 14():1380584. PubMed ID: 38756650
[TBL] [Abstract][Full Text] [Related]
13. Concurrent KRAS p.G12C mutation and ANK3::RET fusion in a patient with metastatic colorectal cancer: a case report.
Bedau T; Heydt C; Siebolts U; Zander T; Kraemer M; Loeser H; Buettner R; Quaas A
Diagn Pathol; 2024 Mar; 19(1):55. PubMed ID: 38539256
[TBL] [Abstract][Full Text] [Related]
14. KRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer.
Xiao A; Fakih M
Clin Colorectal Cancer; 2024 May; ():. PubMed ID: 38825433
[TBL] [Abstract][Full Text] [Related]
15. Discovery of KRB-456, a KRAS G12D Switch-I/II Allosteric Pocket Binder That Inhibits the Growth of Pancreatic Cancer Patient-derived Tumors.
Kazi A; Ranjan A; Kumar M V V; Agianian B; Garcia Chavez M; Vudatha V; Wang R; Vangipurapu R; Chen L; Kennedy P; Subramanian K; Quirke JCK; Beato F; Underwood PW; Fleming JB; Trevino J; Hergenrother PJ; Gavathiotis E; Sebti SM
Cancer Res Commun; 2023 Dec; 3(12):2623-2639. PubMed ID: 38051103
[TBL] [Abstract][Full Text] [Related]
16. Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance.
Lokhandwala J; Smalley TB; Tran TH
Front Oncol; 2024; 14():1394702. PubMed ID: 38841166
[TBL] [Abstract][Full Text] [Related]
17. Probing RAS Function Using Monobody and NanoBiT Technologies.
Whaby M; Nair RS; O'Bryan JP
Methods Mol Biol; 2024; 2797():211-225. PubMed ID: 38570462
[TBL] [Abstract][Full Text] [Related]
18. State-of-the-art and upcoming trends in RAS-directed therapies in gastrointestinal malignancies.
Vanclooster P; Seghers S; Prenen H
Curr Opin Oncol; 2024 Jul; 36(4):313-319. PubMed ID: 38726828
[TBL] [Abstract][Full Text] [Related]
19. Advances in covalent drug discovery.
Boike L; Henning NJ; Nomura DK
Nat Rev Drug Discov; 2022 Dec; 21(12):881-898. PubMed ID: 36008483
[TBL] [Abstract][Full Text] [Related]
20. Targeting KRAS and SHP2 signaling pathways for immunomodulation and improving treatment outcomes in solid tumors.
Sahu P; Mitra A; Ganguly A
Int Rev Cell Mol Biol; 2024; 386():167-222. PubMed ID: 38782499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
